Cargando…

HER2 Status by Standardized Immunohistochemistry and Silver-Enhanced In Situ Hybridization in Korean Breast Cancer

PURPOSE: Amplification of the human epidermal growth factor receptor 2 (HER2) gene occurs in 18% to 20% of breast cancers, and it is recognized as a prognostic and predictive marker. We investigated the HER2 status in Korean breast cancer by immunohistochemistry (IHC) and silver-enhanced in situ hyb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bae, Young Kyung, Gong, Gyungyub, Kang, Jun, Lee, Ahwon, Cho, Eun Yoon, Lee, Ji Shin, Suh, Kwang-Sun, Lee, Dong Wha, Jung, Woo Hee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Breast Cancer Society 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3542844/ https://www.ncbi.nlm.nih.gov/pubmed/23346165 http://dx.doi.org/10.4048/jbc.2012.15.4.381

Ejemplares similares

Positive Expression of Insulin-Like Growth Factor-1 Receptor Is Associated with a Positive Hormone Receptor Status and a Favorable Prognosis in Breast Cancer
por: Shin, Su-Jin, et al.
Publicado: (2014)

Analysis of MET mRNA Expression in Gastric Cancers Using RNA In Situ Hybridization Assay: Its Clinical Implication and Comparison with Immunohistochemistry and Silver In Situ Hybridization
por: Choi, Jiwoon, et al.
Publicado: (2014)

The validation of a novel method combining both HER2 immunohistochemistry and HER2 dual-colour silver in situ hybridization on one slide for gastric carcinoma testing
por: Werner, Dominique, et al.
Publicado: (2014)

Standardized Pathology Report for Breast Cancer
por: Cho, Soo Youn, et al.
Publicado: (2021)

Standardized pathology report for breast cancer
por: Cho, Soo Youn, et al.
Publicado: (2021)

An Optimized Small Tissue Handling System for Immunohistochemistry and In Situ Hybridization
por: Anthony, Giovanni, et al.
Publicado: (2016)

Concomitant Detection of HER2 Protein and Gene Alterations by Immunohistochemistry (IHC) and Silver Enhanced In Situ Hybridization (SISH) Identifies HER2 Positive Breast Cancer with and without Gene Amplification
por: Varga, Zsuzsanna, et al.
Publicado: (2014)

ERG Immunohistochemistry and Clinicopathologic Characteristics in Korean Prostate Adenocarcinoma Patients
por: Suh, Ja Hee, et al.
Publicado: (2012)

Confirmation of a low HER2 positivity rate of breast carcinomas - limitations of immunohistochemistry and in situ hybridization
por: Vogel, Ulrich F
Publicado: (2010)

Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer
por: Sui, Weiguo, et al.
Publicado: (2009)

Evaluation of Immunohistochemistry-Equivocal (2+) HER2 Gene Status in Invasive Breast Cancer by Silver DNA in Situ Hybridization (SISH) and its Association with Clinicopathological Variables
por: A. Musa, Zaidoon, et al.
Publicado: (2017)

Silver-Enhanced In Situ Hybridization as an Alternative to Fluorescence In Situ Hybridization for Assaying HER2 Amplification in Clinical Breast Cancer
por: Park, Kyeongmee, et al.
Publicado: (2011)

Determination of the HER2 amplification status by in situ fluorescent hybridization and concordance with immunohistochemistry for breast cancer samples in Colombia
por: Plata, Adriana, et al.
Publicado: (2013)

Correlation of Immunohistochemistry and Fluorescence in Situ Hybridization for HER-2 Assessment in Breast Cancer Patients: Single Centre Experience
por: Bogdanovska-Todorovska, Magdalena, et al.
Publicado: (2018)

Are There More HER2 FISH in the Sea? An Institution’s Experience in Identifying HER2 Positivity Using Fluorescent In Situ Hybridization in Patients with HER2 Negative Immunohistochemistry
por: Suydam, Camille, et al.
Publicado: (2023)

Low Level of Her-2 Locus Amplification by Fluorescent In Situ Hybridization Does Not Correlate with Her-2 Protein Overexpression by Immunohistochemistry in Barrett's Esophagus
por: Rygiel, Agnieszka M., et al.
Publicado: (2010)

Correlation of AR, EGFR, and HER2 Expression Levels in Prostate Cancer: Immunohistochemical Analysis and Chromogenic In Situ Hybridization
por: Baek, Kwang Hyun, et al.
Publicado: (2012)

Combining Lipophilic dye, in situ Hybridization, Immunohistochemistry, and Histology
por: Duncan, Jeremy, et al.
Publicado: (2011)

Comparison of HER2 status by fluorescence in situ hybridisation and immunohistochemistry in gastric cancer
por: Chen, Ming, et al.
Publicado: (2014)

Evaluation of HER-2/neu status in breast cancer specimens using immunohistochemistry (IHC) & fluorescence in-situ hybridization (FISH) assay
por: Goud, Kalal Iravathy, et al.
Publicado: (2012)

HER-2/neu Amplification Testing in Breast Cancer by Multiplex Ligation-Dependent Probe Amplification in Comparison with Immunohistochemistry and In Situ Hybridization
por: Moelans, Cathy B., et al.
Publicado: (2009)

Evaluating HER2 Gene Amplification Using Chromogenic In Situ Hybridization (CISH) Method In Comparison To Immunohistochemistry Method in Breast Carcinoma
por: Atabati, Hadi, et al.
Publicado: (2018)

Chromogenic in Situ Hybridization Technique versus Immunohistochemistry in Assessment of HER2/neu Status in 448 Iraqi Patients with Invasive Breast Carcinoma
por: Ali, Ali Hussein Mohammed, et al.
Publicado: (2019)

Quantitative analysis of HER2 mRNA expression by RNA in situ hybridization in canine mammary gland tumors: Comparison with immunohistochemistry analysis
por: Seung, Byung-Joon, et al.
Publicado: (2020)

Correlation between HER2/neu protein overexpression on Immunohistochemistry and Fluorescent in Situ Hybridization (FISH) in breast carcinoma: Problems in developing countries
por: Mukhtar, Zubaria, et al.
Publicado: (2023)

Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry
por: Sato-Kuwabara, Yukie, et al.
Publicado: (2009)

HER2 Amplification by Next-Generation Sequencing in Lung Carcinoma: A Comparison of NGS Amplified and Non-amplified Cases by Immunohistochemistry and In Situ Hybridization
por: Kıvrak, Hale, et al.
Publicado: (2022)

Breast implant–associated anaplastic large cell lymphoma: the first South Korean case
por: Lee, Jongwon, et al.
Publicado: (2020)

Breast Carcinoma – A Comparative Study of Immunohistochemistry and Fluorescence in Situ Hybridization for Her-2 Assessment and Association of ER, PR, HER-2 and Ki-67 Expression with Clinico-Pathological Parameters
por: K, Sajitha, et al.
Publicado: (2022)

Dorsal horn-enriched genes identified by DNA microarray, in situ hybridization and immunohistochemistry
por: Sun, Hong, et al.
Publicado: (2002)

Comparative study of in situ hybridization, immunohistochemistry and parasitological culture for the diagnosis of canine leishmaniosis
por: Furtado, Marina C., et al.
Publicado: (2015)

Detection of SARS-CoV-2 by RNAscope(®)in situ hybridization and immunohistochemistry techniques
por: Carossino, Mariano, et al.
Publicado: (2020)

Analysis of reactive astrogliosis in mouse brain using in situ hybridization combined with immunohistochemistry
por: Muraleedharan, Ranjithmenon, et al.
Publicado: (2021)

Droplet digital polymerase chain reaction offers an improvisation over conventional immunohistochemistry and fluorescent in situ hybridization for ascertaining Her2 status of breast cancer
por: Suryavanshi, Moushumi, et al.
Publicado: (2019)

The Use of Immunohistochemistry, Fluorescence in situ Hybridization, and Emerging Epigenetic Markers in the Diagnosis of Malignant Pleural Mesothelioma (MPM): A Review
por: Rozitis, Eric, et al.
Publicado: (2020)

Comparison of Chromogenic In Situ Hybridisation with Fluorescence In Situ Hybridisation and Immunohistochemistry for the Assessment of Her-2/neu Oncogene in Archival Material of Breast Carcinoma
por: Pothos, Alexios, et al.
Publicado: (2008)

Immune repertoire and responses to neoadjuvant TCHP therapy in HER2-positive breast cancer
por: Shin, Junyoung, et al.
Publicado: (2023)

Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)
por: Perez, Edith A., et al.
Publicado: (2013)

HER2 overexpression/amplification status in colorectal cancer: a comparison between immunohistochemistry and fluorescence in situ hybridization using five different immunohistochemical scoring criteria
por: Sun, Qi, et al.
Publicado: (2022)

Is HER2 amplification predictable by digital immunohistochemistry?
por: Micsik, Tamás, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_a1dna7lh6sr2k20k7elje5m9b9